From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Calcium Supplementation in Healthy Nonosteoporotic Men

Calcium supplementation is not just for women.

One quarter of all hip fractures occur in men, and 30% of older men experience fragility fractures. However, data are lacking on calcium supplementation for prevention of osteoporosis in men. In a double-blind trial from New Zealand, 323 healthy men (mean age, 57) with normal bone density were randomized to placebo or to calcium supplementation (600 mg daily or 600 mg twice daily). Men with any major active disease or bone-mineral density (BMD) Z scores lower than –2 were excluded.

During 24 months, total body BMD remained stable in the placebo and low-dose calcium groups but rose by 1.5% in the high-dose calcium group. Lumbar and mean total-hip BMD of high-dose patients rose relative to BMDs in placebo and low-dose patients. Additional biochemical testing, conducted in a randomly selected subgroup, showed a dosage-related decrease in parathyroid hormone and bone turnover. No significant differences were noted in rates of fractures or serious adverse events in all three groups.

Comment: Many argue that sex bias — favoring men — permeates medical research and clinical medicine. Notably, this trial represents an attempt to redress the tendency to study osteoporosis exclusively in women. The results suggest that calcium supplementation is as important for men as it is for women. Additional studies will be required to determine precise dosing regimens (calcium 600 mg daily vs. 600 mg twice daily), the role of vitamin D supplementation in men, and supplementation’s effect on fracture risk.

Jamaluddin Moloo, MD, MPH

Published in Journal Watch General Medicine December 11, 2008

Citation(s):

Reid IR et al. Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med 2008 Nov 10; 168:2276.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Related Content

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2008. Massachusetts Medical Society. All rights reserved.